8-K: Zomedica Reports Record Revenue Growth in 2023, Eyes Continued Expansion in 2024

Zomedica achieved record revenue of $25.2 million in 2023, a 33% increase year-over-year, driven by strong performance in both its diagnostics and therapeutic devices segments.

Summary

• Zomedica reported a record revenue of $7.3 million for the fourth quarter of 2023, and $25.2 million for the full year, representing a 33% annual growth.
• The company's gross margin remained strong at 69% for both the quarter and the full year.
• Revenue growth was primarily driven by a 28% increase in Therapeutic Devices sales and a 252% increase in Diagnostics sales for the full year.
• Consumable revenue grew to $16.4 million, a 41% increase over 2022, and now represents 65% of total revenue.
• Capital revenue reached $8.8 million, a 20% increase over 2022.
• Zomedica completed the acquisitions of Structured Monitoring Products, Inc. and Qorvo Biotechnologies, LLC in 2023.
• The company is projecting full-year 2024 revenue to be in the range of $31 to $35 million, representing a potential 40% increase at the high end of the range.
• The net loss for 2023 was $34.5 million, or $0.035 per share, compared to a net loss of $17.0 million in 2022.
• Non-GAAP EBITDA loss for 2023 was $27.7 million, or $12.8 million when adjusted for one-time items.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue growth and strategic acquisitions, but the net loss and increased operating expenses temper the overall sentiment. The company is on a growth trajectory but needs to manage costs effectively.

Positives

• Zomedica experienced significant revenue growth in 2023, with a 33% increase year-over-year.
• The company maintained a strong gross margin of 69% throughout 2023.
• The Diagnostics segment showed exceptional growth, with a 252% increase in revenue for the year.
• Consumable revenue grew substantially, now representing a larger portion of total revenue.
• The acquisitions of Structured Monitoring Products and Qorvo Biotechnologies are expected to improve margins and product development.
• Zomedica has a strong cash position of $100.5 million as of December 31, 2023.
• The company is projecting continued revenue growth in 2024, with a potential 40% increase at the high end of the range.

Negatives

• Zomedica reported a net loss of $34.5 million for 2023, which is an increase from the $17.0 million loss in 2022.
• Operating expenses increased by 38% in 2023, although when adjusted for one-time items, the increase was 23%, which was lower than the top line growth of 33%.
• The company's Non-GAAP EBITDA loss was $27.7 million for 2023, although this was reduced to $12.8 million when adjusted for one-time items.

Risks

• The company's ability to achieve its revenue targets for 2024 is subject to various risks and uncertainties.
• The company's continued losses and operating expenses could impact its financial stability.
• The company's ability to successfully integrate acquisitions and realize the expected benefits is not guaranteed.
• The company faces competition from other veterinary health companies.
• The company's ability to obtain regulatory approvals for new products is subject to uncertainty.
• The company's reliance on strategic partners for manufacturing and distribution could pose risks.

Future Outlook

Zomedica expects full-year 2024 revenue to be in the range of $31 to $35 million, driven by its existing portfolio, recently launched products, and new product launches planned for 2024. This guidance does not include any potential benefits from acquisitions made during the year.

Management Comments

• Zomedica Chief Executive Officer, Larry Heaton, stated that the company grew full year revenue by over 33% due to early adoption of newly launched products in the Diagnostics segment and continued strength in the Therapeutic Devices segment.
• Mr. Heaton also mentioned that the company believes it is well-positioned to continue its growth trajectory in 2024.
• Mr. Heaton concluded that the progress made in 2023 and planned growth for 2024 moves the company forward on its path to profitability.

Industry Context

Zomedica's growth reflects a broader trend in the veterinary health industry, where demand for advanced diagnostic and therapeutic solutions is increasing. The company's focus on point-of-care diagnostics and therapeutic devices aligns with the industry's move towards more efficient and accessible veterinary care.

Comparison to Industry Standards

• Zomedica's 33% revenue growth in 2023 is strong compared to the overall veterinary health market, which is growing at a more moderate pace.
• Companies like IDEXX Laboratories and Heska Corporation, which are established players in the veterinary diagnostics market, have shown consistent growth, but Zomedica's growth rate is higher.
• Zomedica's 69% gross margin is competitive with industry leaders, indicating efficient cost management.
• The company's focus on acquisitions to expand its product portfolio is a common strategy in the industry, with companies like Zoetis also using acquisitions to drive growth.
• Zomedica's investment in R&D and new product launches is in line with industry trends, as companies seek to innovate and differentiate themselves.

Stakeholder Impact

• Shareholders will likely view the revenue growth and strategic acquisitions positively, but the net loss may cause concern.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to a wider range of veterinary diagnostic and therapeutic products.
• Suppliers may see increased demand for their products and services.
• Creditors may be concerned about the company's net loss but reassured by its strong cash position.

Next Steps

• Zomedica plans to continue to drive increased adoption and utilization of its products.
• The company expects to launch a number of new products during 2024.
• Zomedica will continue to expand its sales and marketing efforts.
• The company will continue to invest in research and development to enhance its current product lines and develop new products.

Key Dates

Keywords

veterinary health, diagnostics, therapeutic devices, revenue growth, gross margin, acquisitions, financial results, Zomedica, TRUFORMA, VetGuardian, TRUVIEW